COVID-19 Testing

Our comprehensive patient-centric solution

includes three tests

SDI Labs’ Covid-19 Testing For Quality Patient Care

Our viral RT-PCR test, antigen test, and antibody test were authorized under FDA (EUA)

Viral RT-PCR RNA Test

Our viral RT-PCR RNA test was authorized under FDA (EUA) in late March and is 99.9% accurate. Our Viral RT-PCR RNA test is used as the first diagnostic method to determine if an active COVID-19 infectious is present in the patient

  • Our viral RT-PCR test was authorized under FDA (EUA) with a proven accuracy rate of 99.9% to diagnose an active COVID-19 infection

  • SDI uses an automated process to return results within 24-72 hours

  • Our test is made in the USA and SDI Labs is licensed to test in all 50 states

Antigen (Rapid Diagnostic) Testing

Antigen testing also referred to as rapid testing, is used to detect active infection. However, antigen testing is less accurate than RT-PCR. It can be used under clinical supervision and with the observation of symptoms to evaluate results.

  • Antigen results may be obtained in less than 15 minutes at the point of care

  • SDI Labs Antigen Kit can be collected with a nasopharyngeal or an anterior nasal swab

  • SDI’s current Antigen Kit has a sensitivity of 92% and a specificity of 100%

Antibody (Serology) Testing

Antibody testing, also known as serology testing, detects signs of a past SARS-CoV-2 infection. It evaluates if a patient has had previous exposure to the virus, developing the antibodies for COVID-19

  • SDI Labs uses antibody testing to detect signs of a past COVID-19infection

  • Our antibody testing provides over 95% specificity, greater than previously available antibody tests

  • Our highly accurate serology testing is used to determine if the patient has developed antibodies to COVID-19

RT-PCR RNA vs Antibody

A COVID-19 test detects an active SARS-CoV-2 virus. An antibody test detects if an individual has had the virus in the past.

There is currently not enough evidence to support the idea that having antibodies guarantees a patient is protected against reinfection with COVID-19.

Better Together

Combining viral RT-PCR RNA tests and antibody tests allows patients to identify both if they are currently infected with COVID-19, and if they may have previously been infected.

With this information, patients have a better understanding of their health history. Meanwhile, employers are able to understand who is currently infected, who has been infected and who has not been. Based on that data, they’re able to make informed decisions about safe societal re-entry.